Phone
Phone
The efficacy is illustrated using nasal mucus infected with SARS-CoV-2, once without and once with the Hexedra+ treatment. The infected cells are labelled with a fluorescent substance.
In the case of the untreated nasal mucus, it can be clearly seen how the coronavirus has already infected a large number of cells after 2 hours. After 24 hours, the extent of the infection of the nasal mucosa is clearly visible.
In the case of the nasal mucosa treated with Hexedra+, it is evident that a significantly lower number of cells are infected after two hours due to the protection with Hexedra+.
The further spread of the coronaviruses is also prevented, so that already after 3 hours 99.9 % fewer cells are infected with the coronavirus compared to the untreated sample.
Safety analysis on nasal epithelial cells after SARS-CoV-2 infection was carried out using MTT assay. The significant negative effects of SARS-CoV-2 on epithelial cell viability can be neutralised by the use of Hexedra+.
The green bars show that the epithelial cells are protected by the protective layer of Hexedra+ from the negative toxic effects of SARS-CoV-2 over a short period of time ranging from 2 hours to a long period of time ranging from 24 hours.
Hexedra+ is a nasal spray based on an active natural ingredient patented (PCT) that offers an effective protection against visus and bacteria transmitted through the nasal mucosa.
Vestatis GmbH is focused on the research, development and marketing of innovative substances which can protect the health and safety of people and facilities.